These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 17898258)
21. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Liu S; Ren S; Howell P; Fodstad O; Riker AI Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528 [TBL] [Abstract][Full Text] [Related]
22. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277 [TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of multiple genes in astrocytic gliomas. Gonzalez-Gomez P; Bello MJ; Arjona D; Lomas J; Alonso ME; De Campos JM; Vaquero J; Isla A; Gutierrez M; Rey JA Int J Oncol; 2003 Mar; 22(3):601-8. PubMed ID: 12579314 [TBL] [Abstract][Full Text] [Related]
24. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362 [TBL] [Abstract][Full Text] [Related]
25. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889 [TBL] [Abstract][Full Text] [Related]
26. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Esteller M Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405 [TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Hou P; Ji M; Yang B; Chen Z; Qiu J; Shi X; Lu Z Cancer; 2006 Apr; 106(7):1602-9. PubMed ID: 16502411 [TBL] [Abstract][Full Text] [Related]
28. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Li B; Liu W; Wang L; Li M; Wang J; Huang L; Huang P; Yuan Y Ann Surg Oncol; 2010 Jul; 17(7):1917-26. PubMed ID: 20112070 [TBL] [Abstract][Full Text] [Related]
29. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073 [TBL] [Abstract][Full Text] [Related]
30. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750 [TBL] [Abstract][Full Text] [Related]
31. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165 [TBL] [Abstract][Full Text] [Related]
32. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. Kang GH; Lee S; Lee HJ; Hwang KS J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506 [TBL] [Abstract][Full Text] [Related]
33. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140 [TBL] [Abstract][Full Text] [Related]
34. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245 [TBL] [Abstract][Full Text] [Related]
35. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chiou HY; Chang JG Oncol Rep; 2004 Feb; 11(2):341-8. PubMed ID: 14719065 [TBL] [Abstract][Full Text] [Related]
36. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737 [TBL] [Abstract][Full Text] [Related]
37. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways. Murao K; Kubo Y; Ohtani N; Hara E; Arase S Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532 [TBL] [Abstract][Full Text] [Related]
38. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847 [TBL] [Abstract][Full Text] [Related]
39. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Li J; El-Naggar A; Mao L Cancer; 2005 Aug; 104(4):771-6. PubMed ID: 15959912 [TBL] [Abstract][Full Text] [Related]
40. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]